Gene-editing drugs advance quickly, but face major challenges

economist.com

Gene-editing drugs are rapidly advancing from research to clinical trials, offering hope for conditions like amyloidosis. In 2020, Patrick Doherty, diagnosed with the disease, participated in a trial and was reportedly cured after a single injection. Despite the promise of these therapies, they still encounter significant technical and economic challenges before widespread availability.


With a significance score of 5.1, this news ranks in the top 1.2% of today's 25041 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Gene-editing drugs advance quickly, but face major challenges | News Minimalist